Monica Holmberg, PharmD, BCPS

The approval carries the limitation that ritlecitinib should not be used in combination with biologic immunomodulators, cyclosporine, other Janus kinase inhibitors, or other potent immunosuppressants.

The approval carries the limitation that bexagliflozin may increase the risk of diabetic ketoacidosis in patients with type 1 diabetes.

Leqembi is an intravenous injection for the treatment of Alzheimer disease.

Adagrasib is a RAS GTPase family inhibitor with objective response rate in patients with certain types of locally advanced or metastatic non–small cell lung cancer (NSCLC).

Tzield does not have any known contraindications.

Eflapegrastim-xnst subcutaneous injection (Rolvedon) reduces infections related to febrile neutropenia in adults with nonmyeloid malignant tumors who are being treated with certain anticancer drugs.

The drug is indicated for moderate to severe plaque psoriasis.

The FDA approved a new azole antifungal for recurrent vulvovaginal candidiasis.

This month's clinical pharmacology update looks at a medication to manage Helicobacter pylori infection in adults.

The FDA has approved glycopyrrolate orally disintegrating tablets (Dartisla ODT; Edenbridge Pharmaceuticals) to reduce symptoms of peptic ulcer as an adjunct to peptic ulcer treatment in adults.

The FDA has approved daridorexant (Quviviq; Idorsia Pharmaceuticals, US Inc) to treat adults with insomnia.

The FDA has approved abrocitinib tablets to treat adults with moderate-to-severe, refractory atopic dermatitis.

TherapeuticsMD, Inc has submitted a supplemental New Drug Application for estradiol and progesterone capsules 0.5 mg/100 mg (Bijuva) to the FDA.

The FDA has approved pilocarpine hydrochloride ophthalmic solution 1.25% (Vuity, Allergan, an AbbVie company) to treat presbyopia in adults.1

The FDA has approved Difelikefalin injection (Korsuva; Cara Therapeutics and Vifor Pharma) for the treatment of moderate-to-severe chronic kidney disease–associated pruritus in adults undergoing hemodialysis.

The FDA has approved atogepant oral tablets (Qulipta; AbbVie) for the preventive treatment of episodic migraines in adults.

The FDA has approved zanubrutinib (Brukinsa, BeiGene) for the treatment of adults with Waldenström macroglobulinemia (WM).